高剂量的利拉格卢提德会损害雌性高血压大鼠的功能
Felipe Tonon Firmino1, Pollyana Peixoto1, Thatiany Jardim Batista1
1Postgraduate Program in Physiological Sciences, Universidade Federal do Espírito Santo, Vitoria, ES, Brazil.
Journal of cardiovascular pharmacology
|November 8, 2024
概括
高剂量的利拉格卢提德会损害高血压大鼠的功能,增加损伤标志物和改变过,尽管GLP-1受体激动剂对心血管有潜在的益处. 较低剂量显示出一些保护作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1受体激动剂 (GLP-1RA) 已知具有心血管方面的益处.
- 在基本高血压模型中,不同剂量的利拉格卢提德对脏的具体影响仍未得到充分研究.
研究的目的:
- 在雌性自发高血压大鼠中研究利拉格卢的剂量依赖性效应.
主要方法:
- 老鼠接受盐水,低剂量 (0.06毫克/公斤),或高剂量 (0.6毫克/公斤) 利拉格卢提德每天两次,持续30天.
- 评估了功能标志物,包括体积分泌量,尿液/血清尿素和肌素比率,以及组织分析 (亚酸盐,酸盐,氧化产物,原).
- 影响评估独立于血压和血糖控制.
主要成果:
- 利拉格卢提德在两个剂量组中都减少了体重增加.
- 高剂量利拉格卢提德增加了尿液体积分泌和/比.
- 高剂量的利拉格卢提德增加了损伤的标志物 (尿素,尿素/肌素比率),增加了原沉积,改变了脏酸盐/酸盐平衡,并异常增加了膜过率.
- 低剂量利拉格卢提德降低了晚期蛋白质氧化产物和尿液尿素/肌素比率.
结论:
- 在基本高血压模型中,利拉格卢提德表现出明显的,剂量依赖的效应.
- 较高剂量的利拉格卢提德似乎会损害功能,并加剧损伤标志物,独立于血压或葡萄糖水平.
- 较低剂量可能会提供一些脏保护性益处,这表明需要在高血压患者中仔细选择剂量.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
500
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
11.9K
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
495
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
495
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:11Renal Failure: Dose Adjustments
67
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
67
01:24Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
01:16Antihypertensive Drugs: Action of Diuretics
623
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
623
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
481
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
481